8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
2024 / Narrative review
This review summarizes recent research on how gut hormones interact with the brain to influence appetite and body weight. Ghrelin acts as an orexigenic hormone, while GLP-1, GIP, CCK, PYY, and OXM act as anorexigenic hormones, with actions extending into systems such as adipose tissue and high-order thinking. Environmental factors, including meal schedule, food contents and quality, exercise type, and sleep deprivation, influence these gut hormone pathways. Additionally, studies show that retatrutide (a triple-agonist of GLP-1, GIP, and glucagon receptor) and orforglipron (a GLP-1 receptor partial agonist) promote weight loss and improve metabolic parameters associated with obesity.
Hong SH, Choi KM Curr Opin Endocrinol Diabetes Obes, 2024. PMID 38511400
2024 / Narrative review
This review examines the relationships between incretin hormones, gut microbiota, and obesity. Gastrointestinal incretins such as GIP and GLP-1 are secreted following nutrient intake and impact lipid metabolism, gastric emptying, appetite, and body weight. The gut microbiota influences host metabolism by modulating incretin secretion via enteroendocrine cells, with microbial metabolites like short-chain fatty acids and indole directly stimulating incretin release. Additionally, incretin-based therapies and bariatric surgery are associated with increases in gut bacterial richness and diversity.
Angelini G, Russo S, Mingrone G Peptides, 2024. PMID 38636809
2024 / Narrative review
This review evaluates the advantages and disadvantages of modern pharmacologic and surgical weight management strategies for obesity. It examines data on anticipated weight loss, glycemic control, cardiometabolic improvements, and possible adverse outcomes associated with incretin-based drugs and bariatric metabolic surgery. The authors note that while lifestyle changes provide health benefits, weight loss from lifestyle alone is modest and hard to sustain.
Singh A, Nissen SE Diabetes Technol Ther, 2024. PMID 38669473
2024 / Narrative review
This narrative review evaluates lean mass loss associated with incretin-based antiobesity medications and the role of resistance exercise. Peptides such as liraglutide, semaglutide, tirzepatide, and retatrutide induce ~15-24% weight loss in adults with overweight and obesity, but also cause rapid loss of lean mass (~10% or ~6 kg). Supervised resistance exercise training interventions longer than 10 weeks can elicit large increases in lean mass (~3 kg) and strength (~25%). The authors propose tailored resistance exercise training alongside incretin therapy to preserve lean mass while achieving fat loss.
Locatelli JC, Costa JG, Haynes A, et al. Diabetes Care, 2024. PMID 38687506
2024 / Narrative review
This narrative review synthesized data on the efficacy and safety of medications approved for long-term obesity management. Compared with lifestyle interventions alone, all approved obesity medications were more effective for long-term weight loss and cardiometabolic improvements. Older medications were associated with mean weight losses of 5-10%, while newer incretin analogues (semaglutide and tirzepatide) were linked to sustained mean reductions of 15-20%. The review notes challenges including cost, availability, weight regain, and loss of lean muscle and bone mineral density.
Qi QYD, Cox A, McNeil S, et al. Osteoarthr Cartil Open, 2024. PMID 38737985
2024 / Narrative review
This review examines the epidemiology and management of gestational diabetes, which affects around 14% of pregnancies globally and incurs US$1.6 billion in direct costs in the USA. Between 30% and 70% of cases are diagnosed before 20 weeks of gestation, with early gestational diabetes associated with worse outcomes than diagnosis at 24 to 28 weeks. Randomized controlled trials demonstrate the benefits of treating gestational diabetes at 24 to 28 weeks, and the TOBOGM trial showed benefits from diagnosing and treating early gestational diabetes in women with risk factors.
Sweeting A, Hannah W, Backman H, et al. Lancet, 2024. PMID 38909620
2024 / Systematic review
This systematic review evaluated the physiological impacts of repeated weight cycling. It found that multiple cycles of weight loss and regain increased central fat deposition, decreased lean mass during weight loss, and increased fat mass during regain. Weight cycling also enhanced adipose tissue inflammation, contributed to pancreatic beta-cell fatigue and failure through hyperinsulinemia and glucose fluctuations, and placed an additional burden on the cardiovascular system. Physical activity combined with calorie restriction was noted to help reduce metabolic disease and chronic inflammation.
Wang H, He W, Yang G, et al. Metabolites, 2024. PMID 38921478
2024 / Narrative review
This review evaluates the available literature on plant-based meat alternatives (PBMAs) and cardiovascular disease (CVD), including their nutritional profiles and impact on CVD risk factors. Compared with meat, PBMAs are usually lower in saturated fat and higher in polyunsaturated fat and dietary fibre. Dietary trials replacing meat with PBMAs have reported improvements in CVD risk factors, including total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B-100, and body weight. The authors note that long-term randomised controlled trials and prospective cohort studies evaluating CVD events are essential to draw more definitive conclusions.
Nagra M, Tsamkiranis F, Ward S, et al. Can J Cardiol, 2024. PMID 38934982
2024 / Narrative review
Societal changes secondary to the COVID-19 pandemic led to an increased prevalence of adolescents with obesity along with heightened awareness of weight stigma and size bias. During this period, the American Academy of Pediatrics issued its first clinical practice guidelines and the FDA approved new weight loss drugs for adolescents, though insurance coverage remains largely unavailable.
Swamy AM Pediatr Clin North Am, 2024. PMID 39003007
2023 / Narrative review
This review evaluates published literature on non-pharmaceutical approaches to COVID-19. It reports that interventions such as regular exercise, adequate sleep, plant-based diets, maintaining a healthy weight, dietary supplementation, and time in nature have been shown to support better COVID-19 outcomes regarding infection risk, severity, and mortality. The authors argue that non-pharmaceutical interventions should not be overlooked, stating that several discussed interventions show risk reductions equivalent to or greater than those associated with available vaccines.
Shows an association, not proof of cause and effect.
Campbell JL J Integr Med, 2023. PMID 36333177
2023 / Scoping review of clinical trials
A scoping review evaluated 389 citations from human clinical trials investigating the effects of oral curcumin on disease outcomes. Nearly half the citations focused on obesity-associated metabolic disorders (29%) or musculoskeletal disorders (17%), with beneficial effects on clinical outcomes and/or biomarkers reported in 75% of these studies (77% of which were double-blind randomized placebo-controlled trials). Trials on neurocognitive (11%), gastrointestinal (10%), or cancer (9%) categories were fewer and reported mixed results depending on study quality and condition. The authors noted the need for systematic evaluation of diverse formulations and doses in larger trials.
Panknin TM, Howe CL, Hauer M, et al. Int J Mol Sci, 2023. PMID 36901908
2023 / Narrative review
This review evaluates the pros and cons of newer weight loss medications like semaglutide and tirzepatide, noting short-term weight losses of -15% to -20% from baseline. The authors note that profound caloric reductions from these medications should prompt baseline or ongoing nutritional deficiency testing and dietary recommendations. However, long-term adherence, cost, access, supply chain issues, and long-term impacts on mental and physical health remain unknown.
Moyad MA Curr Urol Rep, 2023. PMID 37659049
2023 / Narrative review
This review summarizes scientific milestones and therapies developed to address obesity and its cardiometabolic comorbidities. It highlights key developments starting from the discovery of leptin, melanocortin receptor agonists for syndromic obesity, incretin therapies including GLP-1 analogs and unimolecular combinations, and metabolic and bariatric surgery. The authors emphasize that this expanding therapeutic armamentarium warrants a coordinated multidisciplinary approach, such as cardiometabolic expertise centers, to address obesity and its complications.
Kokkorakis M, Katsarou A, Katsiki N, et al. Metabolism, 2023. PMID 37689110
2023 / Interdisciplinary, multi-stakeholder workshop proceedings
An interdisciplinary workshop brought together experts from government, academia, and industry to establish a Research Roadmap concerning processed food intake and obesity and cardiometabolic disease risk in the United States. Attendees highlighted challenges related to heterogeneity and subjectivity in ultra-processed food (UPF; Nova Group 4) classification. They developed six key research questions addressing objective UPF categorization, exposure assessment improvements, independence from diet quality, impacts on ingestive behavior, metabolic responses, and external environmental drivers. The authors conclude that further causal, mechanistic, and methodological research is warranted.
O'Connor LE, Higgins KA, Smiljanec K, et al. Adv Nutr, 2023. PMID 37722488
2023 / Scientific opinion on a health claim
The EFSA NDA Panel evaluated the scientific substantiation of a health claim regarding Appethyl (an aqueous spinach leaf extract) and body weight reduction based on three human intervention studies. Appethyl (5 g/day for 12 weeks) showed no effect on body weight compared to placebo under minimal dietary counselling and moderate physical activity. Additionally, weight maintenance effects (5 g/day for 24 weeks) seen in one study were not replicated, and no evidence was provided for a plausible sustained mechanism in humans. The Panel concluded that a cause-and-effect relationship has not been established under the proposed conditions of use.
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck D, et al. EFSA J, 2023. PMID 37829005
2023 / Narrative review
This review examines semaglutide, approved for type 2 diabetes and obesity management. Manufacturer-sponsored randomized controlled trials showed a loss of almost 12% of body weight over 68 weeks, though individuals regain most of their pretreatment weight once medication is stopped. Gastrointestinal adverse events occur commonly, and pancreatitis, diabetic retinopathy, and severe allergic reactions have also been reported.
Lexchin J, Mintzes B Drug Ther Bull, 2023. PMID 37879878
2023 / Review
Obesity is a major public health concern associated with conditions like hypertension, type 2 diabetes, stroke, and cancer, affecting over a third of adults in the United States. While standard pharmacological agents such as lipase inhibitors and GLP-1 receptor agonists reduce weight gain by inhibiting fat absorption or stimulating satiety hormones, they are not effective for genetic disorders like Bardet-Biedl syndrome or POMC deficiency. Emerging therapies, including leptin analogs and MC4R agonists, target these genetic or hormonal causes to help regulate energy balance and appetite. The review discusses clinical trials, efficacy, FDA-approved indications, contraindications, and serious side effects of these medication classes.
Brandfon S, Eylon A, Khanna D, et al. Cureus, 2023. PMID 37937009
2023 / Narrative review
This narrative review examined position papers published by scientific, professional, and paediatric associations regarding vegan diets during infancy, childhood, and adolescence. Some associations support well-designed vegan diets with vitamin B12 supplementation and medical oversight, while others caution against them, citing potential harm, lack of substantiation, or reliance on lower-quality or outdated studies. The authors highlight the need for an up-to-date literature review and comparable assessments of both omnivorous and vegan diets.
Jakše B, Fras Z, Fidler Mis N Nutrients, 2023. PMID 38004109
2023 / Narrative review
This review evaluates current and future practices for managing tendinopathies of the shoulder, noting that clinical outcomes from randomized controlled trials of standard treatments remain largely unremarkable. Research identifies an association between modifiable lifestyle factors—including smoking, overweight, and physical inactivity—and the onset and persistence of shoulder tendinopathies. The authors suggest using teachable moments and shared decision-making to address these lifestyle factors in clinical care, though further research is needed to determine if this improves clinical outcomes.
Shows an association, not proof of cause and effect.
Littlewood C, Moffatt M, Maher N, et al. Rheumatol Adv Pract, 2023. PMID 38091385
2023 / Editorial
This editorial discusses the multifaceted challenges surrounding weight loss and obesity in science and public health. It highlights that both biological aspects (such as metabolism and the microbiome) and social factors (like poverty and inadequate healthcare) contribute to obesity. While excess weight carries comorbidities that reduce life expectancy, evidence indicates individuals can be overweight and healthy, though obesity remains linked to poor mental health influenced by societal stigma.
Thorp HH Science, 2023. PMID 38096295
2022 / Narrative review
This review evaluated available data on ultra-processed food (UPF) consumption, food intake, and mechanisms related to weight gain and co-morbidities. In primarily observational studies, UPF intake was consistently associated with increased risk of weight gain in adults and children and higher risk of adiposity-related co-morbidities in adults. Additionally, a single mechanistic study showed that UPF consumption led to higher energy intake and weight gain compared to whole foods. The authors note that further mechanistic studies are needed.
Shows an association, not proof of cause and effect.
Crimarco A, Landry MJ, Gardner CD Curr Obes Rep, 2022. PMID 34677812
2022 / Narrative review
This review examines the physiological functions of GLP-1 and its development into pharmaceuticals for obesity and type 2 diabetes (T2DM). GLP-1 receptor agonists are highlighted as effective anti-obesity agents and recommended second-line therapies for T2DM, particularly for patients with increased cardiovascular risk. The author discusses proglucagon processing across tissues and notes that the relationship between endogenous GLP-1 actions and the clinical effects of agonists is far from congruent and generally poorly understood.
Holst JJ J Intern Med, 2022. PMID 34982496
2022 / Statistical report / narrative review
The American Heart Association and the National Institutes of Health compiled the 2022 Statistical Update on heart disease, stroke, and cardiovascular risk factors. It covers core health behaviors such as diet, smoking, physical activity, and weight, as well as health factors including blood pressure, cholesterol, and glucose control. The 2022 edition adds an enhanced focus on social determinants of health, adverse pregnancy outcomes, vascular contributions to brain health, and the global burden of cardiovascular disease.
Tsao CW, Aday AW, Almarzooq ZI, et al. Circulation, 2022. PMID 35078371
2022 / Narrative review
This review summarizes clinical and preclinical evidence regarding the molecular and pharmacological activities of piperine. According to the review, piperine demonstrates antioxidant, anticancer, anti-inflammatory, and antihypertensive properties, and provides therapeutic benefits in conditions including diabetes, obesity, cardiovascular diseases, kidney diseases, and hypertension. These effects are mediated through the modulation of various signaling molecules, enzymes, pathways, and the gut microbiota.
Tripathi AK, Ray AK, Mishra SK Beni Suef Univ J Basic Appl Sci, 2022. PMID 35127957